Real-World lupus drug study launches in poland
NCT ID NCT06673043
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of controlled clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
105 people
The number who actually took part.
- Started
-
Feb 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Consecutive adult (aged ≥18 year old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland. 2. Patients willing to participate in the study and signed Informed Consent Form (ICF). Exclusion Criteria: 1. Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP. 2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lupus erythematosus, systemic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Bydgoszcz, Poland
-
Research Site
Bytom, Poland
-
Research Site
Gdansk, Poland
-
Research Site
Katowice, Poland
-
Research Site
Krakow, Poland
-
Research Site
Lodz, Poland
-
Research Site
Lublin, Poland
-
Research Site
Poznan, Poland
-
Research Site
Rzeszów, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Wroclaw, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe why rheumatic pain feels different for everyone
- Can a new antibody help lupus patients ditch steroids?
- Ear zap may calm lupus pain by taming inflammation
- Engineered immune cells take aim at Hard-to-Treat lupus
- Are women with autoimmune diseases getting the gynecological care they need?
- Can a lupus drug help when given early?